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Summary
 Background To expand access to allogeneic haematopoietic stem cell transplantation (allo-
HSCT) to patients who are ineligible for conventional myeloablative FTBI- or 
busulfan-based preparative regimens, the idea of reduced intensity condition-
ing (RIC) in the early 1990s, and somewhat later in the late 1990s the idea of 
treosulfan-based reduced toxicity conditioning, were created. However, there is 
still need for further optimization of the conditioning regimen for allo – HSCT, 
which should demonstrate sufﬁ cient myeloablative, immunosuppressive and anti-
tumour effects (in the case of malignant disease) along with low early and late 
transplant-related mortality.
 Aim Comparison of infections occurring in children prepared for allogeneic HSCT 
with reduced intensity conditioning (RIC) and treosulfan-based reduced toxici-
ty conditioning regimen (TREO-RTC).
 Material/Methods Data concerning infections in patients conditioned for allogeneic-HSCT with RIC 
and reported in references found using the PubMed database were compared 
with data concerning 51 children prepared for allogeneic HSCT with TREO-RTC 
and reported by Grund et al. (2006).
 Results Following RIC-HSCT the majority of infections occurred beyond day +30. Bacteria 
are leading agents causing infections. The pattern and incidence of fungal infec-
tions are comparable to those observed after myeloablative conditioning, whilst 
incidence of EBV-reactivation and EBV-related disease is increased, but BK-viruria 
is less common. Reported 1-year mortality related to infections after RIC-HSCT is 
around 10%. In 51 children conditioned with TREO-RTC the proﬁ le, incidence 
and timing of infections were comparable to those observed after convention-
al regimens (Grund et al., 2006). Three (5.9%) of them died due to infectious 
complications, one (1.9%) before day +100, and 2 (3.9%) late after transplanta-
tion in the course of extensive chronic GvHD.
 Conclusions Infections remain an issue in children undergoing allogeneic HSCT after RIC or 
TREO-RTC. Therefore prophylaxis, surveillance, early diagnosis and pre-emp-
tive treatment of infections still play an important role in supportive care after 
RIC- and TREO-RTC-HSCT. This approach should be adjusted to the immune 
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BACKGROUND
To expand access to allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) to patients 
who are ineligible for conventional myeloablative 
FTBI- or busulfan-based preparative regimens, the 
idea of reduced intensity conditioning (RIC) in 
the early 1990s [1–3], and somewhat later in the 
late 1990s the idea of treosulfan-based reduced 
toxicity conditioning, were created [4,5].
RIC is deﬁ ned as a regimen demonstrating lit-
tle or no myelosuppression along with intense 
immune suppression sufﬁ cient to prevent an 
immediate rejection of allogeneic haematopoi-
etic stem cells and potency to create an environ-
ment for long-term donor-derived haematopoi-
esis by donor lymphocytes, which – in recipients 
with malignancy – provide an anti-tumour effect 
that maintains disease remission [6]. In practice, 
RIC regimens are characterized by: 1) reversible 
myelosuppression (usually within 28 days) with-
out stem cell support; 2) mixed chimerism in a 
proportion of patients at the time of ﬁ rst assess-
ment, and 3) low rates of non-haematological 
toxicity [7]. Usually RIC consists of one or more 
of the following components: 1) ≤500cGy TBI; 
2) ≤9mg/kg total busulfan dose; 3) ≤140mg/m2 
total melphalan dose, and/or 4) ≤10mg/kg total 
thiotepa dose [6]. Thus, different RIC regimens 
should not be considered equivalent, since their 
anti-neoplastic efﬁ ciency, and their impact on chi-
merism and immune reconstitution, may be dif-
ferent. Over the last 5 years the use of RIC regi-
mens for allo-HSCT has increased signiﬁ cantly. 
According to the last report of CIBMTR among 
13107 registered recipients <20 years of age 716 
(5.5%) have been prepared for allo-HSCT with 
RIC [8]. According to the Third EBMT/AMGEN 
Workshop on RIC Allogeneic HSCT [9] there is 
already evidence that: 1) RIC-HSCT is feasible for 
both malignant and non-malignant diseases, 2) 
after RIC-HSCT and engraftment with long-last-
ing complete donor chimerism can be achieved 
in the majority of patients, 3) there are few graft 
rejections especially when BM is used for RIC-
HSCT, 4) there is reduction of long-term toxicities 
after RIC-HSCT, 5) post RIC-HSCT long-lasting 
responses (>3 years) can be achieved in malig-
nant and non-malignant diseases, but 6) acute 
and chronic GvHD, as well as 7) infectious com-
plications remain an issue after RIC-HSCT. The 
last two factors, i.e. GvHD and infections, are the 
most common obstacles to successful outcome of 
RIC-HSCT [10,11].
Therefore, there is still a need for further op-
timization of the conditioning regimen for al-
lo-HSCT, which should demonstrate sufﬁ cient 
myeloablative, immunosuppressive and anti-tu-
mour effects (in the case of malignant disease) 
along with low early and late transplant-related 
mortality. Availability of such a preparative reg-
imen is crucial in children and adults with sig-
niﬁ cantly increased risk of life-threatening con-
ventional regimen toxicity due to organ injury 
related to primary disease, comorbidities and/or 
previous treatment (including previous autolo-
gous or allogeneic HSCT).
As demonstrated previously by Casper et al. in 
adults [12] and by Wachowiak et al. in children 
reconstitution proﬁ le related to immunosuppressive intensity of the regimen 
and GvHD prophylaxis, donor type, donor/recipient pretranspant viral status, 
stem cell source and GVHD occurrence. Standardization of supportive care af-
ter RIC- and TREO-RTC-HSCT, related to factors which determine risk of infec-
tions, is needed.
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[13] these aims of an optimal preparative regi-
men seemed to be – at least to a signiﬁ cant ex-
tent – achieved with treosulfan-based reduced 
toxicity conditioning (TREO-RTC). In contrast 
to RIC regimens, TREO-RTC demonstrates to-
tal or at least subtotal myeloablative effect and 
standard immunosuppressive effect, but still low 
organ toxicity and satisfactory anti-malignancy ef-
fect. Recently Grund et al. [14] analysed infec-
tious complications in children undergoing allo-
HSCT after conditioning with treosulfan.
AIM
Comparison of morbidity and mortality related 
to infectious complications in children prepared 
for allo-HSCT with reduced intensity condition-
ing (RIC) and with treosulfan-based reduced tox-
icity conditioning (TREO-RTC).
MATERIALS AND METHODS
Data concerning infectious complications in pa-
tients conditioned for allogeneic HSCT with RIC 
and reported in references found using the PubMed 
database were compared with such data concern-
ing 51 children reported on behalf of the Polish 
Paediatric Group for HSCT by Grund et al. [14], 
and 30 adult patients published by Casper et al. [12] 
prepared for allo-HSCT with TREO-RTC.
RESULTS
Infectious complications in children 
conditioned for allogeneic haematopoietic 
stem cell transplantation with reduced intensity 
conditioning regimen
In general, RIC regimens were associated with 
lower rates of severe toxicity and non-relapse 
mortality but, still one-year non-relapse mortal-
ity (NRM) in patients of the RIC regimen was 
signiﬁ cant and amounted to 16% [6,10,11]. In 
contrast to patients undergoing conventional my-
eloablative regimens, in whom most deaths relat-
ed to transplant procedure are observed within 
ﬁ rst 3 months after HSCT, among the recipients 
of RIC regimens majority of deaths occured lat-
er, i.e. between 3 and 6 months post transplanta-
tion. The most common obstacles to successful 
outcome of RIC-HSCT are GvHD and infections. 
Reported 1-year mortality related to infections af-
ter RIC-HSCT is around 10%.
After RIC-HSCT till day +30 the neutropenic fec-
er was observed in 38% of patients [15], however 
the majority of infections occured beyond day 
+30, and at one year 77% patients developed any 
infection [16]. Overall risk of infection is high-
er after RIC-HSCT from an alternative donor. 
Bacteria were the leading agents causing infec-
tions, and the occurrence of bacteriemia at one 
year is 55%, which was mainly caused by coagu-
lase-negative staphylococci, and other Gram-pos-
itive bacteria [16]. The pattern and incidence of 
fungal infections were comparable to those ob-
served after myeloablative conditioning [17]. 
In contrast, following paediatric stem transplan-
tation with RIC the incidence of EBV-reactiva-
tion and EBV-related disease was signiﬁ cantly 
increased, particularly in children with selective 
depletion of recipient T cells following the use of 
ATG [18–20]. BK-viruria and haemorrhagic cys-
titis were less common in patients receiving RIC 
[21]. Risk of CMV infection was increased in pa-
tients  with high-risk CMV serology [16]; however, 
its incidence, like the incidence of other non-bac-
terial infections, correlated with the use of cor-
ticosteroids (Frere, 2006). In non-myeloablative 
HSCT patients the onset of CMV infection was 
signiﬁ cantly delayed in comparison to those re-
ceiving the myeloablative regimen (day +130 ver-
sus day +52), but its overall 1-year incidence was 
similar in both groups of patients [22].
Infectious complications in children 
conditioned for allogeneic haematopoietic 
stem cell transplantation with treosulfan-based 
reduced toxicity conditioning regimen
Recently Grund et al. [14] demonstrated the low 
infection-related death rate in children undergo-
ing allo-HSCT after reduced toxicity condition-
ing with treosulfan (TREO-RTC). Between 2000 
and 2005 a total of 51 children, including 42 with 
haematological malignancies and 9 with congen-
ital disorders, were prepared for allo-HSCT with 
TREO-RTC. Out of 42 patients with usually ad-
vanced haematological malignancies 19 obtained 
HSCT from a matched sibling donor (MSD), and 
23 from a matched unrelated donor (MUD). 
Among 9 children with congenital diseases 5 
were transplanted from MSD, and 4 from MUD. 
As the preparative regimen TREO (3×10–14g/m2) 
was given i.v. in various combinations with other 
cytostatics according to diagnosis, risk factors of 
regimen-related toxicity and/or regimen used 
for ﬁ rst HSCT. Prior MUD-HSCT and in all pa-
tients with congenital disorders ATG (n=27) or 
Campath (n=4) was given. GvHD prophylaxis 
usually consisted of cyclosporine A (CsA) and 
mehotrexate (MTX) (n=24) or CsA (n=18). 
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Infections with high risk of reactivation or pro-
gression occurred prior to HSCT in 16 (31.4%) 
patients. One child was conditioned and trans-
planted in the course of pneumonia.
By day +100 in 42 children with malignancy 38 
infections were documented, including 22 viral 
(52%), 10 bacterial (24%) and 5 fungal (12%). 
Fever of unknown origin (FUO) was observed 
in 5 (12%) patients. One (2.4%) early infec-
tion-related death occurred in a patient who af-
ter MUD-HSCT developed adenovirus infection 
with multiorgan failure (day +66). In addition 2 
(5%) patients died late after MUD-HSCT in the 
course of chronic GvHD due to fungal infection 
(day +634 and +865). By day +100 among 9 chil-
dren with congenital disorders 8 (89%) demon-
strated 13 episodes of infection, including 6 viral 
(46%), 6 bacterial (46%), and one fungal (8%). 
In patients transplanted for congenital disorders 
neither early nor late infection-related deaths oc-
curred. Altogether, three (5.9%) out of 51 pa-
tients studied died as a result of infectious com-
plications, including one (1.9%) before day +100, 
and 2 (3.9%) late after transplantation (both in 
the course of extensive chronic GvHD).
DISCUSSION
The lack of beneﬁ cial effect of RIC on incidence 
of infectious complications may be related to the 
type of patients selected for the regimen, who usu-
ally demonstrate high risk of reactivation of pre-
vious infections. Apart from that RIC regimens 
as well as intensive, usually double GvHD proph-
ylaxis demonstrate highly immunosuppressive ef-
fects. In addition, despite of mentioned above in-
tensive GvHD prophylaxis, RIC-HSCT there is a 
high risk of both acute and chronic GvHD with, 
in addition, so-called “late-onset acute GvHD” 
(after day +100), which may overlap with chron-
ic GvHD [23], and results in an increased risk 
of infections by itself. The increased incidence 
of EBV-related disease following paediatric stem 
cell transplantation with RIC probably reﬂ ects 
the profound immunosuppressive effect of this 
type of conditioning, together with the incom-
plete ablation of recipient-derived B cells [18]. 
It was also demonstrated that the use of alemtu-
zumab in vivo in non-myeloablative condition-
ing may result in a delay in EBV-speciﬁ c T-cell 
recovery [24].
As for TREO-RTC, the proﬁ le, incidence and 
timing of infections observed in children condi-
tioned for allo-HSCT were comparable to those 
observed after conventional regimens. Despite 
the high risk of transplant-related complica-
tions observed before HSCT, the rate of fatal 
infections in the studied group of children was 
low, in both early and late post-HSCT periods. 
However, according to Casper et al. [12] among 
30 adult patients suffering from haematological 
malignancies and prepared for allo-HSCT with 
TREO-RTC, the incidence of non-relapse deaths 
related to infection (unknown origin, days +29, 
+87 and +112) was 10%, i.e. identical to the one 
reported after RIC-HSCT.
CONCLUSIONS
Infections remain an issue in children undergo-
ing allogeneic HSCT after RIC or TREO-RTC. 
Therefore prophylaxis, surveillance, early diag-
nosis and pre-emptive treatment of infections 
still play an important role in supportive care af-
ter RIC- and TREO-RTC-HSCT. This approach 
should be adjusted to immune reconstitution 
proﬁ le related to immunosuppressive intensity of 
regimen and GvHD prophylaxis, donor type, do-
nor/recipient pre-transplant viral status, stem cell 
source and GVHD occurrence. Standardization of 
supportive care after RIC- and TREO-RTC-HSCT 
related to factors which determine the risk of in-
fections is needed.
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